Literature DB >> 15110233

Autoimmune hepatitis: evolving concepts.

Ioannis Diamantis1, Dimitrios T Boumpas.   

Abstract

The liver is continuously exposed to a large antigenic load that includes pathogens, toxins, tumor cells and dietary antigens. A loss of tolerance against its own antigens may result in autoimmune hepatitis (AIH). The current paradigm holds that the disease is the result of self-perpetuating autoimmune process triggered by yet unknown factors (infections, chemicals, drugs) in a genetically susceptible host. To date, several putative hepatocellular surface antigens have been identified: P450-IID6 (recognized by the anti-LKM-1 autoantibodies) a membrane bound asialoglycoprotein receptor (a liver-specific membrane protein), a cytosolic UGA-suppressor tRNA associated protein (recognized by anti-SMA and anti-LP antibodies) and argininosuccinate lysate and formiminotransferase cyclodeaminase (recognized by ant-LC1 antibodies). In contrast to other chronic hepatitides patients with AIH display significant T cell hypereactivity to autologous liver antigens. Tissue injury seems to be mediated by CD4+ or CD8+ T cells and/or by antibody-dependent cell mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110233     DOI: 10.1016/j.autrev.2003.09.003

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  11 in total

Review 1.  Lupus-related hepatitis: complication of lupus or autoimmune association? Case report and review of the literature.

Authors:  Roop Kaw; Carmen Gota; Ana Bennett; David Barnes; Leonard Calabrese
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

2.  Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

Authors:  Karl S Lang; Panco Georgiev; Mike Recher; Alexander A Navarini; Andreas Bergthaler; Mathias Heikenwalder; Nicola L Harris; Tobias Junt; Bernhard Odermatt; Pierre-Alain Clavien; Hanspeter Pircher; Shizuo Akira; Hans Hengartner; Rolf M Zinkernagel
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

Review 3.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

4.  Successful pregnancy in a liver transplant recipient following controlled ovarian hyperstimulation and intracytoplasmic sperm injection.

Authors:  Ulun Ulug; Ali Mesut; Esra Aksoy Jozwiak; Mustafa Bahceci
Journal:  J Assist Reprod Genet       Date:  2005-08       Impact factor: 3.412

5.  Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production.

Authors:  Fouad Lafdil; Hua Wang; Ogyi Park; Weici Zhang; Yuki Moritoki; Shi Yin; Xin Yuan Fu; M Eric Gershwin; Zhe-Xiong Lian; Bin Gao
Journal:  Gastroenterology       Date:  2009-08-15       Impact factor: 22.682

Review 6.  Spatial heterogeneity in the mammalian liver.

Authors:  Shani Ben-Moshe; Shalev Itzkovitz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

7.  Serious liver disease induced by infliximab.

Authors:  Gabriel J Tobon; Carlos Cañas; Juan-Jose Jaller; Juan-Carlos Restrepo; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 3.650

8.  Autoimmune hepatitis in patients with human immunodeficiency virus (HIV): Case reports of a rare, but important diagnosis with therapeutic implications.

Authors:  Leila Kia; Adam Beattie; Richard M Green
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

Review 9.  Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.

Authors:  Loris Riccardo Lopetuso; Giammarco Mocci; Manuela Marzo; Francesca D'Aversa; Gian Lodovico Rapaccini; Luisa Guidi; Alessandro Armuzzi; Antonio Gasbarrini; Alfredo Papa
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

Review 10.  Immunotherapy for liver tumors: present status and future prospects.

Authors:  Pablo Matar; Laura Alaniz; Viviana Rozados; Jorge B Aquino; Mariana Malvicini; Catalina Atorrasagasti; Manuel Gidekel; Marcelo Silva; O Graciela Scharovsky; Guillermo Mazzolini
Journal:  J Biomed Sci       Date:  2009-03-06       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.